Boston Partners lessened its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) by 59.2% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,013 shares of the medical equipment provider’s stock after selling 7,277 shares during the quarter. Boston Partners’ holdings in Lantheus were worth $353,000 as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of LNTH. Vanguard Group Inc. boosted its position in shares of Lantheus by 32.9% in the first quarter. Vanguard Group Inc. now owns 5,742,083 shares of the medical equipment provider’s stock valued at $317,595,000 after acquiring an additional 1,422,269 shares during the period. Eagle Asset Management Inc. bought a new stake in shares of Lantheus in the third quarter valued at about $34,532,000. Deutsche Bank AG raised its stake in Lantheus by 657.4% in the second quarter. Deutsche Bank AG now owns 380,910 shares of the medical equipment provider’s stock valued at $25,152,000 after purchasing an additional 330,620 shares in the last quarter. Fuller & Thaler Asset Management Inc. acquired a new position in Lantheus in the first quarter valued at about $17,813,000. Finally, Renaissance Technologies LLC acquired a new position in Lantheus in the first quarter valued at about $15,865,000. Institutional investors own 97.62% of the company’s stock.
Insiders Place Their Bets
In other news, COO Paul Blanchfield sold 2,432 shares of the company’s stock in a transaction that occurred on Thursday, November 17th. The stock was sold at an average price of $54.79, for a total value of $133,249.28. Following the completion of the transaction, the chief operating officer now owns 73,968 shares of the company’s stock, valued at $4,052,706.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders sold 3,204 shares of company stock valued at $174,443. 1.60% of the stock is currently owned by corporate insiders.
Lantheus Stock Down 0.6 %
Analyst Ratings Changes
A number of research analysts recently commented on LNTH shares. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a research note on Friday, November 4th. SVB Leerink started coverage on Lantheus in a research note on Wednesday, November 30th. They issued an “outperform” rating for the company. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $102.80.
About Lantheus
Lantheus Holdings, Inc engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments.
Featured Articles
- Get a free copy of the StockNews.com research report on Lantheus (LNTH)
- LCI Industries Diversification Strategy Pays Off
- Is It Time To Buy The Dip In The Coca-Cola Company
- Ex-Dividend Date vs. Record Date: What’s the Difference?
- How Does the Consumer Price Index Affect the Stock Market?
- Are Denny’s Corporation Investors Due For A Grand Slam?
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.
-logo.gif&h=45&w=95&zc=2){kind=logo}
